CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE

wherein variables A4, A5, A6, A8, and each of Ra, Rb, R1, R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related t...

Full description

Saved in:
Bibliographic Details
Main Authors RUMFELT Shannon, CHENG Yuan, NISHIMURA Nobuko, PICKRELL Alexander J, LIU Longbin, XUE Qiufen, SIEGMUND Aaron C, MANNING James R, MINATTI Ana Elena, WHITE Ryan D, AMEGADZIE Albert, MA Vu Van, ALLEN Jennifer R, GUZMAN-PEREZ Angel, FROHN Michael J, RZASA Robert M, CHEN Jian J, BROWN James A, LIU Qingyian, NORMAN Mark H, BOURBEAU Matthew P, LOW Jonathan D, PETTUS Liping H, QIAN Wenyuan, HARRINGTON Paul E, NGUYEN Thomas T, STEC Markian M
Format Patent
LanguageEnglish
Published 21.09.2017
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
Online AccessGet full text

Cover

More Information
Summary:wherein variables A4, A5, A6, A8, and each of Ra, Rb, R1, R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.
Bibliography:Application Number: US201615354877